Viburcol — Bioregulatory Approach in Childhood Diseases

Abstract

One of the most urgent problems of modern pediatrics and neonatology is a need for drugs, which, along with proven efficacy, also will have maximal safety for a growing child’s body. This is due to pediatricians, family doctors, narrowly focused pediatric specialists face the fact that highly effective drugs also have a negative impact on the child’s body, have a number of contraindications and age restrictions. The article provides an overview of publications devoted to clinical researches of combination bioregulatory drug Viburcol manufactured by German company Biologische Heilmittel Heel GmbH, which is widely used in childhood diseases both by domestic doctors, and abroad [1, 2, 4–14, 16]. Scientific and clinical studies demonstrate the high efficacy of Viburcol, which in some cases is comparable with that of other drugs [1, 2, 5, 6]. At the same time, Viburcol has a favorable safety profile, is well tolerated by children, is being used from 1 year of age and in pregnant women [1, 2, 4–13].

Keywords

• Viburcol
• bioregulatory approach
• complex bioregulatory drugs
• childhood diseases
• fever
• anxiety in children.